SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-24-000121
Filing Date
2024-05-07
Accepted
2024-05-07 16:05:11
Documents
67
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20240331.htm   iXBRL 10-Q 1317702
2 EX-4.1 a41denali-2024pipexformofp.htm EX-4.1 116132
3 EX-31.1 exhibit311q12024.htm EX-31.1 9891
4 EX-31.2 exhibit312q12024.htm EX-31.2 9911
5 EX-32.1 exhibit321q12024.htm EX-32.1 5550
6 EX-32.2 exhibit322q12024.htm EX-32.2 5679
  Complete submission text file 0001714899-24-000121.txt   6091313

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20240331.xsd EX-101.SCH 42927
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20240331_cal.xml EX-101.CAL 50311
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20240331_def.xml EX-101.DEF 210034
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20240331_lab.xml EX-101.LAB 551876
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20240331_pre.xml EX-101.PRE 383704
71 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20240331_htm.xml XML 660349
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 24921734
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)